Clinical Pharmacology Profile of AMG 119, the First Chimeric Antigen Receptor T (CAR‐T) Cell Therapy Targeting Delta‐Like Ligand 3 (DLL3), in Patients with Relapsed/Refractory Small Cell Lung Cancer (SCLC)
Authors:
- 2 October 2023
- journal article
- research article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 64 (3) , 362-370
Abstract
With the promise of a potentially single‐dose curative regimen, CAR‐T cell therapies have brought a paradigm shift in the treatment and management of hematological malignancies with 6 approved products in the USA. However, there are no approved CAR‐T cell therapies for solid tumors. Herein, we report the clinical pharmacology profile of AMG 119, the first CAR‐T cell therapy targeting delta‐like ligand 3 (DLL3), in patients with relapsed/refractory (R/R) small cell lung cancer (SCLC). AMG 119 demonstrated robust cellular expansion with long‐lasting cell persistence and a favorable exposure–response relationship. AMG 119 has been demonstrated to be clinically safe and well tolerated at the doses tested, with no dose‐limiting toxicities (DLTs) reported. This is the first publication of the clinical pharmacology profile of a CAR‐T cell therapy in SCLC, with encouraging cellular kinetics data supporting the potential for CAR‐T cell therapy in solid tumor space.Keywords
This publication has 21 references indexed in Scilit:
- Efficacy and safety of rovalpituzumab tesirine in patients With DLL3-expressing, ≥ 3rd line small cell lung cancer: Results from the phase 2 TRINITY study.Journal of Clinical Oncology, 2018
- Anti-mesothelin chimeric antigen receptor T cells in patients with epithelial ovarian cancer.Journal of Clinical Oncology, 2016
- Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians GuidelineJournal of Clinical Oncology, 2015
- A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivoScience Translational Medicine, 2015
- Small cell lung cancer: Where do we go from here?Cancer, 2014
- Causes, consequences, and reversal of immune system agingJournal of Clinical Investigation, 2013
- Notch inhibition by the ligand Delta-Like 3 defines the mechanism of abnormal vertebral segmentation in spondylocostal dysostosisHuman Molecular Genetics, 2010
- Bronchopulmonary neuroendocrine tumorsCancer, 2008
- Divergent functions and distinct localization of the Notch ligands DLL1 and DLL3 in vivoJournal of Cell Biology, 2007
- Pharmacokinetic variability of anticancer agentsNature Reviews Cancer, 2005